Literature DB >> 17905334

Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis.

Kimikazu Banba1, Kengo Fukushima Kusano, Kazufumi Nakamura, Hiroshi Morita, Aiko Ogawa, Fuyo Ohtsuka, Keiko Ohta Ogo, Nobuhiro Nishii, Atsuyuki Watanabe, Satoshi Nagase, Satoru Sakuragi, Tohru Ohe.   

Abstract

BACKGROUND: In patients with cardiac sarcoidosis, ventricular arrhythmias and/or conduction disturbances are frequently observed and sometimes fatal. However, few reports on disease activity and arrhythmic events in cardiac sarcoidosis are available.
OBJECTIVE: The purpose of this study was to investigate the relationship between disease activity and arrhythmic events in cardiac sarcoidosis and the effect of corticosteroid therapy.
METHODS: The study population consisted of 15 cardiac sarcoidosis patients with new-onset symptomatic arrhythmia, including eight patients admitted once for complete atrioventricular block (CAVB), five patients admitted once for sustained ventricular tachycardia (VT), and two patients admitted twice for two arrhythmic events (one for CAVB and the other for sustained VT). Disease activity was evaluated by gallium-67 citrate (Ga) scintigraphy. All patients with positive Ga uptake were treated with corticosteroids, and arrhythmic events were evaluated by repeat Holter recordings.
RESULTS: Positive uptake of Ga was observed in 8 (80%) of the 10 CAVB events and in 1 (14%) of the 7 sustained VT events (80% vs 14%, P = .02). Corticosteroids abolished myocardial Ga uptake in all nine patients with positive Ga uptake. After corticosteroid therapy was started, AV conduction improved in 5 of 9 CAVB patients (including 8 patients with new-onset CAVB and one patient with history of CAVB). However, ventricular arrhythmias were not improved after corticosteroid therapy.
CONCLUSION: In cardiac sarcoidosis patients, CAVB develops mainly during the active phase of the disease. Early treatment with corticosteroids might improve AV conduction disturbance. However, sustained VT is not closely linked with disease activity and frequently develops in the advanced stage of disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17905334     DOI: 10.1016/j.hrthm.2007.06.006

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  35 in total

1.  Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis.

Authors:  Kenji Yodogawa; Yoshihiko Seino; Toshihiko Ohara; Hideo Takayama; Takao Katoh; Kyoichi Mizuno
Journal:  Ann Noninvasive Electrocardiol       Date:  2011-04       Impact factor: 1.468

Review 2.  Management of Arrhythmias in Cardiac Sarcoidosis.

Authors:  David G Rosenthal; Paco E Bravo; Kristen K Patton; Zachary D Goldberger
Journal:  Clin Cardiol       Date:  2015-07-14       Impact factor: 2.882

Review 3.  Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis-2018 update: Japanese Society of Nuclear Cardiology recommendations.

Authors:  Shinichiro Kumita; Keiichiro Yoshinaga; Masao Miyagawa; Mitsuru Momose; Keisuke Kiso; Tokuo Kasai; Masanao Naya
Journal:  J Nucl Cardiol       Date:  2019-08       Impact factor: 5.952

4.  Risk assessment of patients with clinical manifestations of cardiac sarcoidosis with positron emission tomography and magnetic resonance imaging.

Authors:  Paco E Bravo; Ganesh Raghu; David G Rosenthal; Shana Elman; Bradley J Petek; Laurie A Soine; Jeffrey H Maki; Kelley R Branch; Sofia C Masri; Kristen K Patton; James H Caldwell; Eric V Krieger
Journal:  Int J Cardiol       Date:  2017-03-10       Impact factor: 4.164

Review 5.  Cardiac sarcoidosis.

Authors:  Matthew M Zipse; William H Sauer
Journal:  Curr Cardiol Rep       Date:  2014-08       Impact factor: 2.931

Review 6.  The role of positron emission tomography in the assessment of cardiac sarcoidosis.

Authors:  Dario Genovesi; Matteo Bauckneht; Corinna Altini; Cristina Elena Popescu; Paola Ferro; Lavinia Monaco; Anna Borra; Cristina Ferrari; Federico Caobelli
Journal:  Br J Radiol       Date:  2019-06-05       Impact factor: 3.039

7.  Comparison of (18)F-fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance (CMR) in corticosteroid-naive patients with conduction system disease due to cardiac sarcoidosis.

Authors:  Hiroshi Ohira; David H Birnie; Elena Pena; Jordan Bernick; Brian Mc Ardle; Eugene Leung; George A Wells; Keiichiro Yoshinaga; Ichizo Tsujino; Takahiro Sato; Osamu Manabe; Noriko Oyama-Manabe; Masaharu Nishimura; Nagara Tamaki; Alexander Dick; Carole Dennie; Ran Klein; Jennifer Renaud; Robert A deKemp; Terrence D Ruddy; Benjamin J W Chow; Ross Davies; Renee Hessian; Peter Liu; Rob S B Beanlands; Pablo B Nery
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-11       Impact factor: 9.236

8.  Ventricular tachycardia as the first manifestation of cardiac sarcoidosis.

Authors:  Felix Mehrhof; Martin Stockburger; Hartwig Schuette; Wilhelm Haverkamp; Rainer Dietz
Journal:  BMJ Case Rep       Date:  2009-04-28

Review 9.  Pathophysiology and clinical management of cardiac sarcoidosis.

Authors:  Nabeel Hamzeh; David A Steckman; William H Sauer; Marc A Judson
Journal:  Nat Rev Cardiol       Date:  2015-02-24       Impact factor: 32.419

10.  Cardiac sarcoidosis, the complete atrioventricular block of which was completely recovered by intravenous steroid pulse therapy.

Authors:  Hiroaki Watanabe; Kazuo Eguchi; Toshinobu Saitou; Masahisa Shimpo; Michiaki Hiroe; Kazuomi Kario
Journal:  J Cardiol Cases       Date:  2015-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.